Melinta Therapeutics Announces Appointment of Christine Ann Miller as President and Chief Executive Officer
August 03 2020 - 7:00AM
Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage company
focused on the development and commercialization of novel
antibiotics, today announced that its Board of Directors has
appointed Christine Ann Miller as President and Chief Executive
Officer and member of the board, effective August 3, 2020.
In April of this year, Melinta became privately
owned by affiliates of healthcare investment firm Deerfield
Management Company, L.P. (“Deerfield”), resulting in a
well-financed and strongly positioned hospital-focused company.
Melinta expects to build upon its existing platform and enhance its
world-class antibiotics portfolio with additional products that
address therapeutic areas of critical need.
“We are pleased that Christine will be joining
Melinta at this pivotal moment,” said Deerfield Partner and Melinta
Board Member Jonathan Leff. “Christine's deep industry
knowledge, successful track record, and
outstanding leadership, will help Melinta to fulfill its
mission in the fight against drug-resistant infections and to grow
its business in other areas of high unmet need.”
Ms. Miller is a global pharmaceutical veteran
with more than 20 years of experience in life sciences. Most
recently, Ms. Miller led the global and U.S. product portfolio for
Sandoz, a $10 billion division of Novartis, where she was
accountable for transitioning the portfolio toward rapid-growth and
higher-margin segments, such as complex generics and value-added
medicines, while continuing to build the branded generics
business.
Among her various achievements, Ms. Miller
directed more than 50 product launches that generated over $300
million of new annual revenue, closed numerous business development
acquisitions, and built a robust five-year development and
acquisition product pipeline. Before Sandoz, Ms. Miller spent
over a decade at Actavis (rebranded as Allergan) and its
predecessor Watson Pharmaceuticals where she led the preparation of
numerous product launches and held leadership roles in both R&D
operations and supply chain management.
Ms. Miller started her career at Merck as a
chemical engineer and procurement analyst and earned an MBA and a
Master in Technology Management at Stevens Institute of Technology
and a B.S. in Chemical Engineering from Rensselaer Polytechnic
Institute.
“I am honored and excited to join Melinta. It is
extremely motivating to see the commitment that this team has to
providing life-saving therapeutic solutions to patients and
customers,” said Ms. Miller, Chief Executive Officer of Melinta.
“Our immediate focus will be to accelerate the customer reach of
our marketed products, including our core brands Vabomere®
(meropenem and vaborbactam) and Orbactiv® (oritavancin), while
expanding our portfolio to serve the critical needs of patients in
the hospital and hospital ecosystem. Together, we will build a high
performing team culture that will enable Melinta to achieve
sustainable growth and fulfill the potential of this tremendous
company.”
With the appointment of Ms. Miller and effective
as of the commencement date of Ms. Miller’s employment, Jennifer
Sanfilippo will step down from her role as Interim Chief Executive
Officer and Director of Melinta and resume her role as Senior Vice
President and General Counsel.
"We would also like to recognize Jennifer
Sanfilippo for her leadership over the past year as Interim Chief
Executive Officer," added Jonathan Leff. "Ms. Sanfilippo has
been instrumental in guiding the organization through the financial
restructuring to effectively position Melinta for future
growth. The Melinta team is extremely grateful for her
service and looks forward to continuing to benefit from her
leadership.”
About Melinta Therapeutics
Melinta Therapeutics, Inc. is the largest
pure-play antibiotics company, dedicated to saving lives threatened
by the global public health crisis of bacterial infections through
the development and commercialization of novel antibiotics that
provide new therapeutic solutions. Its four marketed products
include Baxdela® (delafloxacin), Vabomere® (meropenem and
vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline)
for Injection. This portfolio provides Melinta with the unique
ability to provide providers and patients with a range of solutions
that can meet the tremendous need for novel antibiotics treating
serious infections. Visit www.melinta.com for more information.
Contact Information
Susan Blum(312) 767-0296info@melinta.com
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From May 2024 to Jun 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Jun 2023 to Jun 2024